Advertisement

Substrate in der parenteralen Ernährung

  • R. Breitkreutz
  • T. Gaschott
Chapter
  • 156 Downloads

Zusammenfassung

Die Entwicklung der parenteralen Zufuhr von Flüssigkeiten, Arzneimitteln und Ernährungslösungen erstreckt sich über einen Zeitraum von etwa 350 Jahren. Die ersten Berichte blieben sporadisch und spiegeln in deutlicher Weise das damalige Verständnis von Physiologie und Pathophysiologie wieder.

Literatur

  1. 1.
    Allison SP, Lobo DN, Stanga Z (2001) The treatment of hypoalbumina-emia. Clin Nutr 20:275–279PubMedCrossRefGoogle Scholar
  2. 2.
    Barber MD, Fearon KC, McMillan DC, Slater C, Ross JA, Preston T (2000) Liver export protein synthetic rates are increased by oral meal feeding in weight-losing cancer patients. Am J Physiol Endocrinol Metab 279:E707–E714PubMedGoogle Scholar
  3. 3.
    Ballmer PE (2001) Causes and mechanisms of hypoalbuminaemia. Clin Nutr 20:271–273PubMedCrossRefGoogle Scholar
  4. 4.
    Beck MA, Levander OA (1998) Dietary oxidative stress and the potentiation of viral infection. Annu Rev Nutr 18:93–116 (Review)Google Scholar
  5. 5.
    Beck MA, Shi Q, Morris VC, Levander OA (1995) Rapid genomic evolution of a non-virulent coxsackievirus B3 in selenium-deficient mice results in selection of identical virulent isolates. Nat Med 1:433–436PubMedCrossRefGoogle Scholar
  6. 6.
    Bérard MP, Zazzo JF, Condat P, Vasson MP, Cynober L (2000) Total parenteral nutrition enriched with arginine and glutamate generates glutamine and limits protein catabolism in surgical patients hospitalized in intensive care units. Crit Care Med 28:3637–3644PubMedCrossRefGoogle Scholar
  7. 7.
    Borum PR. Supplements: questions to ask to reduce confusion. Am J Clin Nutr 2000 72:S538–S5340 (Review)Google Scholar
  8. 8.
    Breitkreutz R, Pittack N, Nebe C-T et al. (2000) Improvement of immune functions in HIVinfection bysulphuraminoacid supplementation. J Mol Med 78:55–62PubMedCrossRefGoogle Scholar
  9. 9.
    Breitkreutz R, Holm S, Pittack N et al. (2000) Massive loss of sulphur in HIV-infection. AIDS Res Hum Retroviruses 16:203–209PubMedCrossRefGoogle Scholar
  10. 10.
    Breitkreutz R, Babylon A, Hack V et al. (2000) Effect of carnitine on muscular glutamate uptake and intramuscular glutathione in malignant diseases. Br J Cancer 82:399–403PubMedCrossRefGoogle Scholar
  11. 11.
    Buchman AL (2001) Glutamine: commercially essential or conditionally essential? A critical appraisal of the human data. Am J Clin Nutr 74:25–32 (Review)Google Scholar
  12. 12.
    Calder PC, Yaqoob P (1999) Glutamine and the immune system. Amino Acids 17:227–241 (Review)Google Scholar
  13. 13.
    Careaga G, Salazar D, Tellez S et al. (2001) Clinical impact of histidine-ketoglutarate-tryptophan (htk) cardioplegic solution on the perioperative period in open heart surgery patients. Arch Med Res 32:296–299PubMedCrossRefGoogle Scholar
  14. 14.
    Cochrane Injuries Group Albumin Reviewers [No authors listed] (1998) Human albumin administration in critically ill patients: systematic review of randomised controlled trials. BMJ 25:235–240Google Scholar
  15. 15.
    Cynober L (1991) Ornithine alpha-ketoglutarate in nutritional support. Nutrition 7:313–322PubMedGoogle Scholar
  16. 16.
    De Caro L, Ghizzi A, Costa R et al. (1989) Pharmacokinetics and bioavailability of oral acetylcysteine in healthy volunteers. Arzneimittelforsch 39:382–386PubMedGoogle Scholar
  17. 17.
    Dröge W, Breitkreutz R (1999) N-acetylcysteine in the therapy of HIV-positive patients. Curr Opin Clin Nutr Metab Care 2:493–498PubMedCrossRefGoogle Scholar
  18. 18.
    Dröge W, Breitkreutz R (2000) Glutathione and immune function. Proc Nutr Soc 59:1–6CrossRefGoogle Scholar
  19. 19.
    Dröge W, Holm E (1997) Role of cysteine and glutathione in HIV infection and other diseases associated with muscle wasting and immunological dysfunction. FASEB J 11:1077–8109 (Review)Google Scholar
  20. 20.
    Evoy D, Lieberman MD, Fahey TJ 3rd, Daly JM (1998) Immunonutrition: the role of arginine. Nutrition 14:611–617 (Review)Google Scholar
  21. 21.
    Feldman EB (1999) Creatines dietary supplement and ergogenic aid. Nutr Rev 57:45–50Google Scholar
  22. 22.
    Finelli C, Alfano V, Pasanisi F et al. (2001) Use and abuse of albumin: a survey of clinical records from an internal medicine ward. Clin Nutr 20: 183–185PubMedCrossRefGoogle Scholar
  23. 23.
    Fürst P (1998) Old and new substrates in clinical nutrition. J Nutr 128: 789–796 (Review)Google Scholar
  24. 24.
    Fürst P, Stehle P (1994) Parenteral nutrition substrates. In: Payne-James JJ, Grimble G, Silk DBA (eds.) Artificial nutrition support in clinical practice. Arnold, London, pp 301–322Google Scholar
  25. 25.
    Gikic M, Di Paolo ER, Pannatier A, Cotting J (2000) Evaluation of physi-cochemical incompatibilities during parenteral drug administration in a paediatric intensive care unit. Pharm World Sei 22:88–91CrossRefGoogle Scholar
  26. 26.
    Green AL, Hultman E, Macdonald IA, Sewell DA, L. Greenhaff P (1996) Carbohydrate ingestion augments skeletal muscle creatine accumulation during creatine supplementation in humans. Am J Physiol 271: 1–6Google Scholar
  27. 27.
    Greenhaff PL (1997) The nutritional biochemistry of creatine. Nutr Biochem 8:610–618CrossRefGoogle Scholar
  28. 28.
    Grimble RF, Grimble GK (1998) Immunonutrition: role of sulfur amino acids, related amino acids, and polyamines. Nutrition 14:605–610 (Review)Google Scholar
  29. 29.
    Hack V, Breitkreutz R, Kinscherf R et al. (1998) The redox state as a correlate of senescence and wasting and as a target for therapeutic intervention. Blood 92:59–67PubMedGoogle Scholar
  30. 30.
    Hack V, Schmid D, Breitkreutz R et al. (1997) Cystine levels,cystine flux, and protein catabolism in cancer cachexia, HIV/SIV-infection and senescence. FASEB J 11:84–92PubMedGoogle Scholar
  31. 31.
    Holm E, Staedt U, Leweling H, Tokus M (1993) Metabolism and artificial nutrition of patients with malignancy. SA J Clin Nutr 6:10–21Google Scholar
  32. 32.
    Holm E, Breitkreutz R,Tokus M (2000) Metabolic encephalopathies: liver disease, renal failure and critical illness. In: Fernström JD, Uauy R, Arroyo P (eds) Nutrition and brain, Vol 5, Nestlé Nutrition Workshop Series:Clinical & Performance Programme. Karger, Basel, pp 283–306Google Scholar
  33. 33.
    Holt S, Goodier D, Marley R et al. (1999) Improvement in renal function in hepatorenal syndrome with N-acetylcysteine. Lancet 353: 294–295PubMedCrossRefGoogle Scholar
  34. 34.
    Jahoor F, Gazzard B, Phillips G et al. (1999) The acute-phase protein response to human immunodeficiency virus infection in human subjects. Am J Physiol 276:E1092–E1108PubMedGoogle Scholar
  35. 35.
    Jonas CR, Griffith DP, Bergman GF, Leader LM, Ziegler TR (2001) Nutrient Pharmacotherapy. In: Rombeau JL, Rolandelli R (eds) Clinical nutrition: parenteral nutrition, 3rd edn. Saunders, Philadelphia, chap. 28, pp 562–579Google Scholar
  36. 36.
    Magnusson I, Ekman L, Wangdahl M, Wahren J (1989) N-acetyl-L-tyrosine and N-acetyl-L-cysteine as tyrosine and cysteine precursors during intravenous infusion in humans. Metabolism 38:957–961PubMedCrossRefGoogle Scholar
  37. 37.
    Mirtallo JM (2001) Parenteral formulas. In: Rombeau JL, Rolandelli R (eds) Clinical nutrition: parenteral nutrition, 3rd edn. Saunders, Philadelphia, chap. 7, pp 118–139Google Scholar
  38. 38.
    Newsholme E, Hardy G (1997) Supplementation of diets with nutritional pharmaceuticals. Nutrition 13:837–839PubMedCrossRefGoogle Scholar
  39. 39.
    Nordenström J (1999) Metabolic complications of parentertal nutrition. In: Payne-James JJ, Grimble G, Silk DBA (eds) Artificial nutrition support in clinical practice. Arnold, London, pp 333–342Google Scholar
  40. 40.
    Parenteral nutrition - A pocket guide (Driscoll DF, Mirtallo JM, Helms Ra,Bistrian BR,editoral advisory board), Astra Zeneca,LPGoogle Scholar
  41. 41.
    Pauling L (1991) Vitamins and intelligence tests. Nature 353:103PubMedCrossRefGoogle Scholar
  42. 42.
    Puchstein C (1999) Die Entwicklung der parenteralen Ernährung. In: Lawin P, Opderbecke W, Schuster HP (Hrsg) Die geschichtliche Entwicklung der Intensivmedizin in Deutschland. Anästhesist 48: 827–837Google Scholar
  43. 43.
    Razenberger M, Spittler A, Roth E (1998) Zytoprotektive und immunmodulierende Eigenschaften von Glyzin. Akt Ernährungsmed 23: 269–274Google Scholar
  44. 44.
    Rebouche CJ, Seim H (1998) Carnitine metabolism and its regulation in microorganisms and mammals. Annu Rev Nutr 18:39–61 (Review)Google Scholar
  45. 45.
    Rössle C, Pichard C, Roulet M, Bergström J, Fürst P (1989) Muscle carnitine pools in cancer patients. Clin Nutr 8:341–346PubMedCrossRefGoogle Scholar
  46. 46.
    Roth E (1998) The impact of L-arginine-nitric oxide metabolism on ischemia/reperfusion injury.Curr Opin Clin Nutr Metab Care 1:97–99 (Review)PubMedCrossRefGoogle Scholar
  47. 47.
    Roth E, Funovics J, Schulz F, Karner J (1980) Biochemical methods for the determination of a clinical protein catabolism.lnfusionsther. Klin Ernähr 7:306–309Google Scholar
  48. 48.
    Schmoz G (1994). Ernährungszustand. In: Hartig W (Hrsg) Moderne Infusionstherapie - Künstliche Ernährung. Zuckschwerdt, Müchen, S 169–179Google Scholar
  49. 49.
    Shenkin A, Allwood MC (2001) Trace elements and vitamins in adult intravenous nutrition. In: Rombeau JL, Rolandelli R (eds) Clinical nutrition: parenteral nutrition, 3rd edn. Saunders, Philadelphia, chap.4, pp 61–79Google Scholar
  50. 50.
    Shenkin A (2001) Micronutrients in adult nutritional support: requirements and benefits. Clin Nutr 20:S47–S50CrossRefGoogle Scholar
  51. 51.
    Shronts EP (1997)Essential nature of choline with implications for total parenteral nutrition. J Am Diet Assoc 97:639-646; 649; quiz 647–648PubMedCrossRefGoogle Scholar
  52. 52.
    Smilkstein MJ, Bronstein AC, Linden C et al. (1991) Acetaminophen overdose: a 48-hour intravenous N-acetylcysteine treatment protocol. Ann Emerg Med 20:1058–1063PubMedCrossRefGoogle Scholar
  53. 53.
    Takeuchi K, Maida KJanaka S et al. (1999) Superior myocardial protection with a new histidine-buffered crystalloid cardioplegic solution in clinical trial. Thorac Cardiovasc Surg 47:148–152PubMedCrossRefGoogle Scholar
  54. 54.
    Tepel M, van der Giet M, Schwarzfeld C et al. (2000) Prevention of radi-ographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 343:180–184PubMedCrossRefGoogle Scholar
  55. 55.
    Taut F, Zaplethal CM, Klar E et al. (1999) Sulfur-containing metabolites of N-acetyl-cysteine in patients undergoing orthotopic liver transplantation. Transplant Proc 31:411–413PubMedCrossRefGoogle Scholar
  56. 56.
    Trissel LA, Gilbert DL, Martinez JF et al. (1999) Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN J Parenter Enteral Nutr 23:67–74PubMedCrossRefGoogle Scholar
  57. 57.
    Valencia E, Marin A, Hardy G (2001) Glutathione-nutritional and pharmacological viewpoints: part III. Nutrition 17:696–697PubMedCrossRefGoogle Scholar
  58. 58.
    Walker R, Lupien JR (2000).The safety evaluation of monosodium glutamate. J Nutr 130: S1049–S1052 (Review)Google Scholar
  59. 59.
    Wu G, Meininger CJ, Knabe DA, Bazer FW, Rhoads JM (2000) Argini-ne nutrition in development, health and disease. Curr Opin Clin Nutr Metab Care 3:59–66 (Review)PubMedCrossRefGoogle Scholar
  60. 60.
    Zeisel SH, Da Costa KA, Franklin PD et al. (1991) Choline, an essential nutrient for humans. FASEB J 5:2093–2098PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • R. Breitkreutz
  • T. Gaschott

There are no affiliations available

Personalised recommendations